---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-037205"
form_type: "8-K"
ticker: "OPRX"
cik: "0001448431"
company_name: "OptimizeRx Corp"
filed_at: "2024-04-29T23:59:59+00:00"
generated_at: "2026-06-03T05:29:17.482113+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# OptimizeRx prelim Q1 revenue $18.5-19.2M (+40% YoY); ahead of consensus

## Summary
- Revenue expected between $18.5M and $19.2M for Q1 2024, over 40% growth YoY; GAAP net loss $(8.2)-$(7.0)M.
- Adjusted EBITDA loss of $(1.0)-$(0.7)M; results driven by DAAP platform and October 2023 Medicx acquisition.
- Signed 9 new Dynamic Audience Activation Platform (DAAP) deals in Q1; cross-selling ahead of internal expectations.
- Medicx integration ahead of schedule; management estimates $2.8B potential opportunity from existing brands alone.
- Earnings call scheduled for May 14, 2024 at 4:30 p.m. ET to discuss full Q1 results.

## SEC filing metadata
- accession: 0001213900-24-037205
- form_type: 8-K
- ticker: OPRX
- cik: 0001448431
- company_name: OptimizeRx Corp
- filed_at: 2024-04-29T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1448431/000121390024037205/0001213900-24-037205-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1448431/000121390024037205/ea0204901-8k_optimizer.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-037205
- JSON: https://secwatch.observer/filing/0001213900-24-037205.json
- Plain text: https://secwatch.observer/filing/0001213900-24-037205.txt

## Key facts
- Earnings Releases
  OptimizeRx Corp reported first quarter for the period ended March 31, 2024 results: revenue between $18.5 million and $19.2 million.
  - Period: first quarter for the period ended March 31, 2024
  - Revenue: between $18.5 million and $19.2 million
  - Result: preliminary results
  source text: the Company expects revenue to increase over 40% year-over-year and come in between $18.5 million and $19.2 million with a GAAP net loss and Adjusted EBITDA loss between $(8.2) - $(7.0) million and $(1.0) - $(0.7) million, respectively
  evidence_url: https://www.sec.gov/Archives/edgar/data/1448431/000121390024037205/0001213900-24-037205-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.